PACB
Income statement / Annual
Last year (2024), Pacific Biosciences of California, Inc.'s total revenue was $154.01 M,
a decrease of 23.19% from the previous year.
In 2024, Pacific Biosciences of California, Inc.'s net income was -$308.65 M.
See Pacific Biosciences of California, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$154.01 M |
$200.52 M |
$128.30 M |
$130.51 M |
$78.89 M |
$90.89 M |
$78.63 M |
$93.47 M |
$90.71 M |
$92.78 M |
Cost of Revenue |
$116.73 M
|
$147.74 M
|
$79.27 M
|
$71.65 M
|
$46.33 M
|
$56.32 M
|
$53.53 M
|
$58.81 M
|
$46.55 M
|
$39.33 M
|
Gross Profit |
$37.28 M
|
$52.78 M
|
$49.04 M
|
$58.86 M
|
$32.57 M
|
$34.58 M
|
$25.10 M
|
$34.66 M
|
$44.16 M
|
$53.45 M
|
Gross Profit Ratio |
0.24
|
0.26
|
0.38
|
0.45
|
0.41
|
0.38
|
0.32
|
0.37
|
0.49
|
0.58
|
Research and Development Expenses |
$134.92 M
|
$187.17 M
|
$193.00 M
|
$112.90 M
|
$64.15 M
|
$59.63 M
|
$62.59 M
|
$65.32 M
|
$67.62 M
|
$60.44 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
$45.19 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$175.02 M
|
$169.82 M
|
$160.85 M
|
$124.12 M
|
$72.80 M
|
$75.49 M
|
$63.49 M
|
$59.12 M
|
$47.79 M
|
$45.19 M
|
Other Expenses |
$83.72 M
|
$30.26 M
|
$7.64 M
|
$93,000.00
|
$2.06 M
|
$1.02 M
|
$848,000.00
|
$516,000.00
|
$103,000.00
|
$364,000.00
|
Operating Expenses |
$393.66 M
|
$387.25 M
|
$353.85 M
|
$237.02 M
|
$136.95 M
|
$135.12 M
|
$126.08 M
|
$124.44 M
|
$115.40 M
|
$105.63 M
|
Cost And Expenses |
$510.40 M
|
$534.99 M
|
$433.12 M
|
$308.68 M
|
$183.28 M
|
$191.44 M
|
$179.61 M
|
$183.25 M
|
$161.96 M
|
$144.96 M
|
Interest Income |
$0.00
|
$0.00
|
$14.69 M
|
$12.53 M
|
$267,000.00
|
$2.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
-$13.41 M
|
$14.34 M
|
$14.69 M
|
$12.53 M
|
$267,000.00
|
$2.61 M
|
$2.42 M
|
$2.92 M
|
$3.23 M
|
$2.93 M
|
Depreciation & Amortization |
$0.00
|
$26.53 M
|
$17.32 M
|
$11.59 M
|
$9.30 M
|
$9.95 M
|
$7.22 M
|
$8.44 M
|
$3.88 M
|
$3.68 M
|
EBITDA |
-$356.38 M |
-$277.28 M |
-$282.24 M |
-$250.76 M |
$38.97 M |
-$71.58 M |
-$92.92 M |
-$80.83 M |
-$67.27 M |
-$25.09 M |
EBITDA Ratio |
-2.31
|
-1.38
|
-2.32
|
-1.36
|
-1.3
|
-1.09
|
-1.27
|
-0.96
|
-0.74
|
-0.56
|
Operating Income Ratio |
-2.31
|
-1.67
|
-2.38
|
-1.37
|
-1.32
|
-1.11
|
-1.28
|
-0.96
|
-0.79
|
-0.31
|
Total Other Income/Expenses Net |
$48.05 M
|
$16.31 M
|
-$9.43 M
|
-$96.71 M
|
$133.79 M
|
$16.41 M
|
-$1.58 M
|
-$2.41 M
|
-$3.13 M
|
-$2.56 M
|
Income Before Tax |
-$308.34 M
|
-$318.16 M
|
-$314.25 M
|
-$274.87 M
|
$29.40 M
|
-$84.13 M
|
-$102.56 M
|
-$92.19 M
|
-$74.38 M
|
-$31.70 M
|
Income Before Tax Ratio |
-2
|
-1.59
|
-2.45
|
-2.11
|
0.37
|
-0.93
|
-1.3
|
-0.99
|
-0.82
|
-0.34
|
Income Tax Expense |
$316,000.00
|
-$11.42 M
|
-$17.32 M
|
-$93.65 M
|
-$6.98 M
|
-$6.32 M
|
$848,000.00
|
-$5.01 M
|
$3.34 M
|
-$387,000.00
|
Net Income |
-$308.65 M
|
-$306.74 M
|
-$296.93 M
|
-$181.22 M
|
$29.40 M
|
-$77.82 M
|
-$102.56 M
|
-$92.19 M
|
-$74.38 M
|
-$31.70 M
|
Net Income Ratio |
-2
|
-1.53
|
-2.31
|
-1.39
|
0.37
|
-0.86
|
-1.3
|
-0.99
|
-0.82
|
-0.34
|
EPS |
-1.12 |
-1.21 |
-1.32 |
-0.89 |
0.18 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
-0.42 |
EPS Diluted |
-1.07 |
-1.21 |
-1.32 |
-0.89 |
0.17 |
-0.51 |
-0.76 |
-0.87 |
-0.83 |
-0.42 |
Weighted Average Shares Out |
$274.49 M
|
$253.63 M
|
$224.46 M
|
$203.62 M
|
$172.96 M
|
$152.53 M
|
$134.95 M
|
$105.68 M
|
$89.15 M
|
$75.61 M
|
Weighted Average Shares Out Diluted |
$288.37 M
|
$253.63 M
|
$224.55 M
|
$204.14 M
|
$174.97 M
|
$152.53 M
|
$135.09 M
|
$105.68 M
|
$89.15 M
|
$75.61 M
|
Link |
|
|
|
|
|
|
|
|
|
|